Early experience with tedizolid: Clinical efficacy, pharmacodynamics, and resistance

Pharmacotherapy

Volumn 34, Issue 11, 2014, Pages 1198-1208

  Rybak, Jeffrey M ^a   Marx, Kayleigh ^a   Martin, Craig A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

infectious disease; oxazolidinone; pharmacodynamic; resistance; tedizolid

Indexed keywords

CHLORAMPHENICOL; FLORFENICOL; LINEZOLID; METICILLIN; OXAZOLIDINONE DERIVATIVE; RIBOSOME PROTEIN; TEDIZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; NEW DRUG; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; PRODRUG;

ABSCESS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUROPATHY; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; POINT MUTATION; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT INDICATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORGANOPHOSPHATES; OXAZOLES; PRODRUGS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84909956314     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1491     Document Type: Article

References (50)

1. Jones RN,. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42: S13-24.
2. Kelesidis T, Humphries R, Uslan DZ, Pegues DA,. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 2: 228-34.
3. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 6: 821-5.
4. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 22: 2260-4.
5. Brown SD, Traczewski MM,. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010; 5: 2063-9.
6. Gregory WA, Brittelli DR, Wang CL, et al. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group. J Med Chem 1990; 9: 2569-78.
7. Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010a; 12: 5337-43.
8. Livermore DM, Mushtaq S, Warner M, Woodford N,. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009; 4: 713-5.
9. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 2: 583-92.
10. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012; 5: 2627-34.
11. Flanagan SD, Bien PA, Munoz KA, Minassian SL, Prokocimer PG,. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014; 34 (3): 240-50. doi: 10.1002/phar.1337.
12. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 1: 73-7.
13. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 10: 1389-91.
14. Legout L, Senneville E, Gomel JJ, Yazdanpanah Y, Mouton Y,. Linezolid-induced neuropathy. Clin Infect Dis 2004; 5: 767-8.
15. Hosako H, Radovsky A, Draganov DI, Vija J, Bartizal K,. Lack of Neuropathy after Long-Term Tedizolid Administration in Rats. Proceedings of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO, USA; September 10-13, 2013.
16. Waldrep TW, Skiest DJ,. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 2002; 1: 109-12.
17. Lund JE, Brown PK,. Hypersegmented megakaryocytes and megakaryocytes with multiple separate nuclei in dogs treated with PNU-100592, an oxazolidinone antibiotic. Toxicol Pathol 1997; 4: 339-43.
18. Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 3: 382-7.
19. Pharmaceuticals C. Sivextro (tedizolid phosphate) tablets and injection. FDA Briefing Document Anti- Infective Drug Advisory Committee Meeting. 2014.
20. Prokocimer P, Bien P, Munoz KA, Aster R,. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. Proceedings of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, USA; October 25-28, 2008.
21. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P,. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 7: 3060-6.
22. Huang V, Gortney JS,. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 12: 1784-93.
23. Pratt LA, Brody DJ, Gu Q,. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 2011; 76: 1-8.
24. De Anda C, Fang E, Das A, Prokocimer P,. Integrated Results from Phase 3 Studies Comparing Tedizolid 6 Days vs Linezolid 10 Days in Patients with ABSSSI. Proceedings of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO, USA; September 10-13, 2013.
25. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 1: 79-86.
26. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ,. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 15: 1411-23.
27. Louie A, Liu W, Kulawy R, Drusano GL,. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 7: 3453-60.
28. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR,. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012; 11: 5916-22.
29. Andes D, van Ogtrop ML, Peng J, Craig WA,. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 11: 3484-9.
30. Keel RA, Tessier PR, Crandon JL, Nicolau DP,. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 2012a; 8: 4403-7.
31. Andes D, Craig WA,. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 6: 1665-70.
32. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM,. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009; 5: 1035-43.
33. Drusano GL, Liu W, Kulawy R, Louie A,. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 11: 5300-5.
34. Keel RA, Crandon JL, Nicolau DP,. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 2012b; 6: 3420-2.
35. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP,. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 2012; 5: 2342-6.
36. Zurenko G, Todd WM, Hafkin BA,. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, USA; September 26-29, 1999.
37. Yoshida K, Shoji H, Hanaki H, et al. Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J Infect Chemother 2009; 6: 417-9.
38. Ntokou E, Stathopoulos C, Kristo I, et al. Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2012; 8: 1819-23.
39. Kadlec K, Fessler AT, Hauschild T, Schwarz S,. Novel and uncommon antimicrobial resistance genes in livestock-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2012; 8: 745-55.
40. Kaatz GW, Seo SM,. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 3: 799-801.
41. Billal DS, Feng J, Leprohon P, Legare D, Ouellette M,. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 2011; 12: 512. doi: 10.1186/1471-2164-12-512.
42. Tsakris A, Pillai SK, Gold HS, et al. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus. J Antimicrob Chemother 2007; 3: 649-51.
43. Tazi A, Chapron J, Touak G, et al. Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient. Antimicrob Agents Chemother 2013; 10: 5186-8.
44. Locke JB, Morales G, Hilgers M, et al. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob Agents Chemother 2010b; 12: 5352-5.
45. Quiles-Melero I, Garcia-Perea A, de Pablos M, Gomez-Gil R, Mingorance J,. Resistance to linezolid in a methicillin-susceptible Staphylococcus aureus clinical isolate without previous exposure to oxazolidinones. Int J Med Microbiol 2012; 3: 145-7.
46. Arias CA, Vallejo M, Reyes J, et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008; 3: 892-6.
47. Yang XJ, Chen Y, Yang Q, et al. Emergence of cfr-harbouring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China. J Med Microbiol 2013b; 62 (Pt 6): 845-50.
48. Baos E, Candel FJ, Merino P, Pena I, Picazo JJ,. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 3: 325-9.
49. Shen J, Wang Y, Schwarz S,. Presence and dissemination of the multiresistance gene cfr in gram-positive and gram-negative bacteria. J Antimicrob Chemother 2013; 8: 1697-706.
50. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012; 1: 51-4.